Key result
Oral administration of ivabradine successfully reduced heart rate and increased cardiac output, enabling the discontinuation of intravenous catecholamines in a patient with severe decompensated heart failure.
Why the study?
Does oral ivabradine allow discontinuation of intravenous catecholamines in a patient with decompensated heart failure and low cardiac output syndrome?
Case Report (n=1)
No
Does oral ivabradine allow discontinuation of intravenous catecholamines in a patient with decompensated heart failure and low cardiac output syndrome?
Oral ivabradine may safely reduce heart rate and improve cardiac output in patients with severe HFrEF and sinus tachycardia, facilitating weaning from intravenous catecholamines.
May facilitate catecholamine weaning in select decompensated HFrEF; hypothesis-generating and requires prospective trials.
Ivabradine has been shown to improve heart failure with sinus tachycardia by reducing the heart rate without affecting left ventricular systolic function or blood pressure. Here we report a case of a catecholaminedependent patient, New York Heart Association (NYHA) class IV, LVEF of 18%, and low cardiac output, who was able to discontinue intravenous catecholamine by oral administration of ivabradine.
No takes yet. Share an insight, caveat, or question.
Shibata et al. (2021) conducted a case report in Decompensated heart failure with low cardiac output syndrome (n=1). Oral ivabradine was evaluated on Discontinuation of intravenous catecholamine. Oral administration of ivabradine successfully reduced heart rate and increased cardiac output, enabling the discontinuation of intravenous catecholamines in a patient with severe decompensated heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: